IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
PRE 14A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
Fastest customizable press release news feed in the world
All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in pa
PITTSBURGH, Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced that Jonathan Kaufman, Chief Executive Officer of Lipella, will present a corporate overview and final results from Phase 2a trial of LP-10 in oral lichen planus at the Zacks SCR Life Sciences Virtual Investor Forum on September 18th, 2025 at 12:30pm EDT. Event Details: To register for the event and access the Lipella presentation webcast, click on th
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec
PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ("Cook MyoSite") to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, "We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 (liposomal tacrolimus oral rinse) for the treatment of Oral Lichen Planus (OLP) will be presented at the 2025 joint international meeting of the American Academy of Oral Me
Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at
Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites. Topline results from the final cohort (1.0 mg) remain on track for the second quarter of 2025 and will represent the most
This live feed shows all institutional transactions in real time.
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)